corticosteroids, whereas they showed a measurable clinical response and remained in remission for a long time after the last treatment.
Background and Aims: Lung cancer is the leading cause of cancer-related mortality worldwide. Most patients are diagnosed at an advanced stage without noticeable symptoms. Nicotine, as the major addictive component in cigarettes, may be involved in the progression of lung cancer cells after a long term exposure. The present study investigates the potential effectors of long-term nicotine exposure in lung cancer.
Methods: cDNA microarray was firstly used to explore the potential effectors of long-term nicotine exposure in the parental squamous lung cancer cells, H157, and H157N, harvested with nicotine (10 μM) for 2 years. The bioinformatics platform was used to analyze whether the mRNA expression of various effectors might contribute to patient survival.
Results: There were 5 transcripts (CXCR4, VEGFA, TP73, IL-1β, WNT5A) (>2-fold intensity) were significantly increased and associated with several pathways (i.e. Activation of MAPK activity, positive regulation of protein phosphorylation, response to hypoxia and ion transport). Accordingly, the Kaplan-Meier survival curves of patient groups with CXCR4, VEGFA, TP73 and IL-1β significantly predicted a worse overall survival of lung cancer patient. Intriguingly, high WNT5A mRNA levels improved patient survival in 1926 lung cancer cases (P = 0.003) but unexpectedly associated with a poor survival rate in those patients with smoking history (P = 0.005).
Conclusion:
Our results suggested that the interplay of long term nicotine exposure and WNT5A related signalling might play roles in lung cancer. The exact roles and underlying mechanisms of the WNT5A related signalling as well as its interplay with nicotine demand further investigations in particular those lung cancer patients with smoking history. Background and Aims: Pulmonary rehabilitation (PR) has been reported to prevent postoperative pulmonary complications and improve reduced pulmonary function after lobectomy. This study aimed to characterize the recovery of respiratory muscle strength, exercise capacity, and dyspnea after lobectomy in patients with non-small cell lung cancer (NSCLC) undergoing PR.
Methods: A total of 37 patients with NSCLC who underwent single lobectomy (15 males and 22 females, mean age 6 AE years, mean hospital stay 1 AE days) were enrolled for this study. They performed protocolized PR, including breathing exercises, endurance and resistance training, from 1-2 weeks before to 3 months after lobectomy. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), maximal inspiratory (MIP) and expiratory (MEP) mouth pressures, quadriceps strength (QS), 6-minute walk distance (6MWD), and modified Medical Research Council (mMRC) dyspnea grade were evaluated preoperatively, at discharge, and at 1 and 3 months after lobectomy. This study was approved by the Institutional Review Board for Clinical Research, Tokai University (17R-389).
Results: At discharge, FVC, FEV 1 , MIP, MEP and 6MWD were lower than preoperative values (72%, 72%, 79%, 66%, and 87% of preoperative values, respectively) and mMRC grade was impaired (median: 1 [interquartile range: 1-2]), but QS did not change. From discharge to 3 months after lobectomy, all parameters improved. At 3 months after lobectomy, MIP, MEP, QS, and 6MWD improved to 114%, 100%, 110%, and 104%
of preoperative values, respectively; FVC and FEV 1 did not reach preoperative values (84% and 85%, respectively). mMRC grade at 3 months after lobectomy (0 [0-1]) did not change from preoperative value.
We found that after single lobectomy for patients with NSCLC undergoing protocolized PR, 1) respiratory muscle strength, exercise capacity, and dyspnea recover to preoperative levels by 3 months, and 2) pulmonary function does not reach preoperative levels until at least 3 months. The studies concerning about frequency of driver mutations in patients with lung adenocarcinoma have great population-based diversity. A prospective study of medical centres in Taiwan had showed the frequency of EGFR mutations in lung adenocarcinoma was 55% and ALK rearrangement was 9.8% in EGFR-wild type lung adenocarcinoma. The aim of this study was to analyze these driver mutations among patients diagnosed of lung adenocarcinoma in a local hospital of Taiwan.
Methods: A retrospective cohort study was conducted for the analysis of driver mutations status among patients with newly-diagnosed lung adenocarcinoma in Chen Ching hospital, a local hospital in Taiwan. Two common driver mutations (EGFR mutation and ALK rearrangement) were identified by the pharmacogenomics Lab, National Research Program for
